Elon Musk’s Neuralink often sparks images of a sci-fi future. Yet, behind the hype, the company is pursuing two very different, complex goals on parallel tracks. One is restoring movement, and the other, vision, but both are in early stages.
The 'Telepathy' Trial in Action
Neuralink’s
most publicised effort is the PRIME Study, nicknamed 'Telepathy'. Its first participant, Noland Arbaugh, who is paralyzed from the shoulders down, received the implant in early 2024. The brain-computer interface (BCI) translates his intended movements into commands, allowing him to control a computer cursor with his thoughts. He has used it to play online chess, browse the internet, and even play Mario Kart. The journey hasn't been without issues; weeks after surgery, some of the device's ultra-thin threads retracted from his brain, reducing its effectiveness. While Neuralink's engineers compensated for this with software adjustments, the incident highlights the immense technical challenges involved. A second participant, identified as Alex, received an implant in mid-2024, with the company implementing new techniques to reduce the risk of thread retraction.
The Next Frontier: Restoring Vision
Separate from the Telepathy trials is Neuralink's even more ambitious goal: restoring vision with a project called 'Blindsight'. This technology is fundamentally different. Instead of reading motor intent from the brain, it aims to 'write' visual information into it. The concept involves using a camera to capture images and translating that data into patterns of electrical stimulation delivered directly to the brain's visual cortex. The goal is to create a form of synthetic sight for people who are blind. While the company has announced recent progress and received a 'Breakthrough Device Designation' from the US Food and Drug Administration (FDA) to help speed up review, human trials for Blindsight have not yet begun. Elon Musk has stated the technology is ready from an engineering standpoint, but it is still awaiting regulatory clearance to start clinical tests.
Why Are They Separate Projects?
The Telepathy and Blindsight projects tackle fundamentally different neurological challenges. The Telepathy implant for paralysis is a 'read' device; it listens to the motor cortex to decode a person's intention to move. It is an output system, turning thought into digital action. In contrast, the Blindsight implant is a 'write' device. It's an input system designed to send external sensory information—in this case, simplified visual data from a camera—into the brain to be processed as sight. This distinction is crucial. Reading existing neural signals is a monumental task, but creating artificial sensory perception by stimulating the cortex is arguably a higher-order challenge. Each requires unique hardware, software, and surgical approaches, explaining why they are developed on separate, independent tracks.
The Reality of Limited Clinical Testing
The headline's mention of 'limited clinical testing' is a critical piece of context. Despite the global attention, Neuralink's human trials are in their infancy. As of late 2026, only a small number of participants are enrolled in the PRIME study. Medical device approval is a long, multi-phase process that takes years of rigorous testing to prove both safety and effectiveness. Early issues, like the thread retraction in the first patient, are part of this scientific process. While Neuralink has received FDA approval to expand its trials and has opened recruitment for more participants, the technology remains strictly investigational. The company's approach of announcing progress via social media and company blogs, rather than through peer-reviewed scientific journals, has also drawn criticism for prioritising public excitement over clinical transparency.
